首页|养血生发汤联合复方倍他米松注射液治疗斑秃患者的临床疗效观察

养血生发汤联合复方倍他米松注射液治疗斑秃患者的临床疗效观察

扫码查看
目的 探讨养血生发汤联合复方倍他米松注射液治疗斑秃的临床疗效。方法 100例斑秃患者,按照随机数字表法分为对照组和治疗组,各 50 例。对照组采用复方倍他米松注射液治疗,治疗组采用养血生发汤联合复方倍他米松注射液治疗。比较两组临床疗效,毛发生长情况,脱发面积和部位评分、轻拉发实验评分和皮肤病生活质量指数量表(DLQI)评分,免疫功能,不良反应和复发率。结果 治疗组治疗总有效率 96。00%高于对照组的 84。00%(P<0。05)。治疗后,两组脱发区毛发再生情况、新生毛发密度、新生毛发粗细、新生毛发色泽评分均低于治疗前,且治疗组脱发区毛发再生情况、新生毛发密度、新生毛发粗细、新生毛发色泽评分分别为(1。54±0。32)、(0。84±0。19)、(0。87±0。20)、(0。72±0。13)分,均低于对照组的(2。28±0。40)、(1。20±0。27)、(1。28±0。23)、(1。09±0。20)分(P<0。05)。治疗后,两组脱发面积和部位评分、轻拉发实验评分、DLQI评分均低于治疗前,且治疗组脱发面积和部位评分、轻拉发实验评分、DLQI评分分别为(0。51±0。12)、(0。51±0。10)、(3。48±0。72)分,低于对照组的(0。84±0。16)、(0。68±0。12)、(6。51±1。15)分(P<0。05)。治疗后,两组CD4+、CD8+水平均低于治疗前,且治疗组CD4+(39。71±5。03)%、CD8+(21。32±3。60)%均低于对照组的(42。90±5。87)%、(23。01±3。84)%(P<0。05)。两组不良反应发生率比较无差异(χ2=1。042,P=0。307>0。05)。治疗结束后随访 3 个月,治疗组复发率 2。00%(1/50)低于对照组的 16。00%(8/50)(χ2=5。983,P=0。014<0。05)。结论 养血生发汤联合复方倍他米松注射液治疗斑秃安全有效,可促进患者毛发生长,改善其免疫功能,减少其复发,利于加速其康复进程。
Observation on clinical effect of Yangxue Shengfa decoction combined with compound betamethasone injection in the treatment of patients with alopecia areata
Objective To explore the clinical efficacy of Yangxue Shengfa decoction combined with compound betamethasone injection in the treatment of alopecia areata.Methods 100 patients with alopecia areata were divided into a control group and a treatment group according to the random numerical table,with 50 patients in each group.The control group was treated with compound betamethasone injection,while the treatment group was treated with Yangxue Shengfa decoction and compound betamethasone injection.The clinical efficacy,hair growth,hair loss area and site score,light hair-pulling test score,dermatology life quality index(DLQI)score,immune function,adverse reactions and recurrence rate were compared between the two groups.Results The total effective rate of the treatment group was 96.00%,which was higher than 84.00%of the control group(P<0.05).After treatment,the scores of hair regeneration in the hair loss area,new hair density,new hair thickness and new hair color in both groups were lower than those before treatment;the scores of hair regeneration in the hair loss area,new hair density,new hair thickness and new hair color in the treatment group were(1.54±0.32),(0.84±0.19),(0.87±0.20)and(0.72±0.13)points,which were lower than(2.28±0.40),(1.20±0.27),(1.28±0.23)and(1.09±0.20)points in the control group(P<0.05).After treatment,the hair loss area and site score,light hair-pulling test score and DLQI score in both groups were lower than those before treatment;the hair loss area and site score,light hair-pulling test score and DLQI score in the treatment group were(0.51±0.12),(0.51±0.10)and(3.48±0.72)points,which were lower than(0.84±0.16),(0.68±0.12)and(6.51±1.15)points in the control group(P<0.05).After treatment,CD4+ and CD8+ levels in both groups were lower than those before treatment;the treatment group had CD4+ of(39.71±5.03)%and CD8+ of(21.32±3.60)%,which were lower than(42.90±5.87)%and(23.01±3.84)%in the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(χ2=1.042,P=0.307>0.05).After 3 months of follow-up,the recurrence rate in the treatment group was 2.00%(1/50),which was lower than 16.00%(8/50)in the control group(χ2=5.983,P=0.014<0.05).Conclusion The combination of Yangxue Shengfa decoction and compound betamethasone injection is safe and effective in the treatment of alopecia areata,which can promote hair growth,improve immune function,reduce recurrence,and accelerate the recovery process.

Alopecia areataYangxue Shengfa decoctionCompound betamethasone injectionClinical efficacy

周潇

展开 >

255300 淄博市中医医院皮肤科

斑秃 养血生发汤 复方倍他米松注射液 临床疗效

淄博市医药卫生科研项目

20231503102

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(7)
  • 20